A Study of LY3437943 in Healthy Participants With a High Body Mass Index

NCT05959096 · Completed

Last updated 2026-05-28

This clinical trial is testing the effects of the drug LY3437943 on healthy adults who have a high body mass index to see how the body processes it.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 85 people

Who can join Ages 18–70 · all sexes Healthy volunteers accepted.

Timeline Started 2023-07 · est. completion 2024-07

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05959096 ↗

Description as written by the study sponsor.

The study is conducted in two parts (Part A and B). The main purpose of this study is to look at the amount of the LY3437943 that gets into the blood stream and how long it takes the body to get rid of it when given subcutaneously (SC, under the skin) in the upper arm and thigh compared to the abdomen in healthy participants with high body mass index (BMI) in Part A. In Part B, the participants receive LY3437943 intravenously (IV, through a vein) where the safety and tolerability of LY3437943 are evaluated and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately up to 157 days and 99 days for Part A and Part B, respectively.

Treatments tested

LY3437943 Drug

Administered SC
LY3437943 Drug

Administered IV

Main thing measured	Part A: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05959096 ↗